Ibrutinib

Ibrutinib

Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.

Specifications

Product Name:                  Ibrutinib

Synonyms:                         N/A

CAS Number:                     936563-96-1

Molecular Weight:            440.5036

Molecular Formula:          C25H24N6O2

Purity (HPLC):                     ≥99%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               C=CC(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1ccc(cc1)Oc1ccccc1

  • $200.00
  • Ex Tax: $200.00

Available Options